Detection in whole blood of autoantibodies for the diagnosis of connective tissue diseases in near patient testing condition

PLoS One. 2018 Aug 30;13(8):e0202736. doi: 10.1371/journal.pone.0202736. eCollection 2018.

Abstract

A novel technology, photonic ring immunoassay (PRI), for detecting 12 autoantibodies simultaneously in whole blood in less than 15 minutes was evaluated by comparing results from 235 clinically diagnosed patients with standard laboratory tests. The overall agreement was greater than 91% for 10 of the 12 assays, with positive percent agreement greater than 89% for 9 of the assays and negative percent agreement greater than 91% for 10 of them. Thus, the clinical sensitivities and specificities were similar for the 2 methods. In addition, 199 normal blood donors were tested on the ANA 12 PRI, yielding specificities greater than 97.5% for all assays. This proof of concept study shows that this new system is suitable for point of care testing for clinically useful autoantibodies, allowing the doctor to have test results in minutes rather than days.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies / blood*
  • Blood Donors
  • Connective Tissue Diseases / diagnosis*
  • Humans
  • Immunoassay / methods*
  • Laboratories
  • Sensitivity and Specificity

Substances

  • Autoantibodies

Grant support

Funding for the study (materials, arrays etc.) was provided by Genalyte Inc. SM, AW and RB are Genalyte Inc employees. The funder provided support in the form of salaries for authors SM, AW and RB, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.